◀ Back to SRC

SRC — TTC37

Text-mined interactions from Literome

Rapecki et al., J Pharmacol Exp Ther 2002 : The activity of these compounds [ named CT-SKI ( Celltech Src kinase inhibitors ) ] was investigated by assessing their potential to modulate T cell receptor activation, an event thought to involve the Src kinases Lck and Fyn
Konig et al., Blood 2008 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : We investigated whether SKI-606 , a potent Bcr-Abl and Src kinase inhibitor without anti-PDGF or c-Kit activity, could effectively target primitive CML progenitors ... SKI-606 effectively inhibited Bcr-Abl kinase activity in CML CD34 ( + ) cells and inhibited Src phosphorylation more potently than imatinib ... SKI-606 effectively inhibits Bcr-Abl and Src kinase activity and inhibits CML progenitor growth with relatively little effect on normal progenitors
Vultur et al., Mol Cancer Ther 2008 (Breast Neoplasms) : SKI-606 ( bosutinib ), a novel Src kinase inhibitor , suppresses migration and invasion of human breast cancer cells ... We examined the effects of SKI-606 ( bosutinib ), a selective Src family kinase inhibitor , on human cancer cells derived from breast cancer patients to assess its potential for breast cancer treatment
Kim et al., Clin Cancer Res 2012 (Cell Transformation, Neoplastic...) : SKI-606 , an Src inhibitor , reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer ... SKI-606 effectively inhibited aberrant activation of Src and its downstream targets to markedly inhibit the growth of thyroid tumor, thereby prolonging the survival of treated mice